BioLine RX Ltd
BLRX
View Detailed Chart
3.040USD
+0.080+2.70%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.23MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.70%
5 Days
-8.16%
1 Month
-8.71%
6 Months
-33.48%
Year to Date
-64.49%
1 Year
-62.38%
View Detailed Chart
TradingKey Stock Score of BioLine RX Ltd
Currency: USD Updated: 2025-12-19Key Insights
BioLine RX Ltd's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 183/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioLine RX Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
26.000
Target Price
+683.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioLine RX Ltd Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.94M.
Overvalued
The company’s latest PE is -2.10, at a high 3-year percentile range.
BioLine RX Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioLine RX Ltd Info
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Ticker SymbolBLRX
CompanyBioLine RX Ltd
CEOSerlin (Philip Adam)
Websitehttps://www.biolinerx.com/
FAQs
What is the current price of BioLine RX Ltd (BLRX)?
The current price of BioLine RX Ltd (BLRX) is 3.040.
What is the symbol of BioLine RX Ltd?
The ticker symbol of BioLine RX Ltd is BLRX.
What is the 52-week high of BioLine RX Ltd?
The 52-week high of BioLine RX Ltd is 14.696.
What is the 52-week low of BioLine RX Ltd?
The 52-week low of BioLine RX Ltd is 2.300.
What is the market capitalization of BioLine RX Ltd?
The market capitalization of BioLine RX Ltd is 13.23M.
What is the net income of BioLine RX Ltd?
The net income of BioLine RX Ltd is -9.22M.
Is BioLine RX Ltd (BLRX) currently rated as Buy, Hold, or Sell?
According to analysts, BioLine RX Ltd (BLRX) has an overall rating of Buy, with a price target of 26.000.
What is the Earnings Per Share (EPS TTM) of BioLine RX Ltd (BLRX)?
The Earnings Per Share (EPS TTM) of BioLine RX Ltd (BLRX) is -1.446.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
